GlassScriptPhysician profile
Ashley Wood
NPI 1013504976
$4,981.78
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,746 · 2022: $1,667 · 2023: $1,458 · 2024: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,150.44 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $488.50 | 2021-2023 | Farxiga, Fasenra |
| Glaxosmithkline, LLC. | $413.08 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.10 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $345.12 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Vanda Pharmaceuticals INC. | $234.05 | 2021-2022 | |
| Pfizer INC. | $189.23 | 2021-2023 | |
| Amgen INC. | $178.75 | 2021-2023 | Repatha, Evenity, Prolia |
| Teva Pharmaceuticals USA, INC. | $132.30 | 2021 | |
| Endo Pharmaceuticals INC. | $125.37 | 2021-2022 | |
| Novo Nordisk INC | $119.25 | 2021-2023 | Wegovy |
| Lundbeck LLC | $114.25 | 2021-2023 | Rexulti |
| Genentech USA, INC. | $84.22 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $79.55 | 2021-2023 | Rexulti |
| Myriad Women'S Health, INC. | $74.25 | 2023 | Myrisk |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.